Sano Women’s Health is developing next-generation therapeutics at the intersection of women’s health and oncology. Our pipeline includes clinical and preclinical programs targeting recurrent vulvovaginal candidiasis (RVVC), postpartum infections, and breast cancer, supported by our proprietary HOAM (Higher-Order Actin Modulating) Discovery Platform. By advancing novel actin-modulating therapeutics, we aim to address diseases where current treatment options remain limited or inadequate.
Our Pipeline
Platform Therapeutics
Sano Women’s Health is advancing a pipeline of novel antifungal, antibacterial, and oncology therapeutics powered by proprietary platform technologies, including occidiofungin, mutacin-derived compounds and the HOAM (Higher-Order Actin Modulating) Discovery Platform. Through unique higher-order actin modulating and antimicrobial mechanisms, our programs are being developed to address diseases with significant unmet medical need, including recurrent fungal infections, postpartum infections, drug-resistant bacterial infections, and aggressive solid tumors. Current programs span Phase 2 clinical development through preclinical discovery across women’s health, infectious disease, and oncology indications.
